These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2432921)

  • 1. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.
    Medof ME; Walter EI; Roberts WL; Haas R; Rosenberry TL
    Biochemistry; 1986 Nov; 25(22):6740-7. PubMed ID: 2432921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage.
    Walter EI; Roberts WL; Rosenberry TL; Ratnoff WD; Medof ME
    J Immunol; 1990 Feb; 144(3):1030-6. PubMed ID: 1688588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases.
    Roberts WL; Kim BH; Rosenberry TL
    Proc Natl Acad Sci U S A; 1987 Nov; 84(22):7817-21. PubMed ID: 3479767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells.
    Walter EI; Ratnoff WD; Long KE; Kazura JW; Medof ME
    J Biol Chem; 1992 Jan; 267(2):1245-52. PubMed ID: 1370460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decay-accelerating factor (DAF) shares a common carbohydrate determinant with the variant surface glycoprotein (VSG) of the African Trypanosoma brucei.
    Davitz MA; Gurnett AM; Low MG; Turner MJ; Nussenzweig V
    J Immunol; 1987 Jan; 138(2):520-3. PubMed ID: 2432127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C.
    Roberts WL; Myher JJ; Kuksis A; Low MG; Rosenberry TL
    J Biol Chem; 1988 Dec; 263(35):18766-75. PubMed ID: 2848806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D.
    Metz CN; Brunner G; Choi-Muira NH; Nguyen H; Gabrilove J; Caras IW; Altszuler N; Rifkin DB; Wilson EL; Davitz MA
    EMBO J; 1994 Apr; 13(7):1741-51. PubMed ID: 7512501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drosophila acetylcholinesterase: demonstration of a glycoinositol phospholipid anchor and an endogenous proteolytic cleavage.
    Haas R; Marshall TL; Rosenberry TL
    Biochemistry; 1988 Aug; 27(17):6453-7. PubMed ID: 2975507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.
    Medof ME; Walter EI; Rutgers JL; Knowles DM; Nussenzweig V
    J Exp Med; 1987 Mar; 165(3):848-64. PubMed ID: 2434600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional forms of human decay-accelerating factor (DAF).
    Seya T; Farries T; Nickells M; Atkinson JP
    J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro attachment of glycosyl-inositolphospholipid anchor structures to mouse Thy-1 antigen and human decay-accelerating factor.
    Fasel N; Rousseaux M; Schaerer E; Medof ME; Tykocinski ML; Bron C
    Proc Natl Acad Sci U S A; 1989 Sep; 86(18):6858-62. PubMed ID: 2476803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
    Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
    Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.
    Carothers DJ; Hazra SV; Andreson SW; Medof ME
    J Clin Invest; 1990 Jan; 85(1):47-54. PubMed ID: 1688570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol-anchored glycoproteins of PC12 pheochromocytoma cells and brain.
    Margolis RK; Goossen B; Margolis RU
    Biochemistry; 1988 May; 27(9):3454-8. PubMed ID: 3390445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of amine components in a glycolipid membrane-binding domain at the C-terminus of human erythrocyte acetylcholinesterase.
    Haas R; Brandt PT; Knight J; Rosenberry TL
    Biochemistry; 1986 Jun; 25(11):3098-105. PubMed ID: 3524671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of decay accelerating factor (DAF) by a two-step procedure and determination of its N-terminal sequence.
    Davitz MA; Schlesinger D; Nussenzweig V
    J Immunol Methods; 1987 Feb; 97(1):71-6. PubMed ID: 2434569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.